For research purposes only. Not for human consumption.
Description:
CJC-1295 (No DAC), also known as Modified GRF (1-29), is a synthetic peptide analogue derived from growth hormone-releasing hormone (GHRH). Through targeted amino acid substitutions, the peptide was designed to improve stability while maintaining structural similarity to naturally occurring GHRH sequences. It has become a widely studied compound within peptide chemistry, endocrinology, and receptor pharmacology research.
Researchers have investigated CJC-1295 (No DAC) in laboratory settings to better understand peptide-mediated signalling pathways, receptor interactions, pharmacokinetic characteristics, and neuroendocrine regulatory mechanisms. Its modified structure and receptor-binding profile have contributed to ongoing scientific interest in studies examining hormone signalling and peptide pharmacology.
Current scientific investigations continue to evaluate CJC-1295 (No DAC)'s molecular behaviour, stability characteristics, receptor activation dynamics, and biological activity within controlled experimental environments. Ongoing research seeks to further characterize its mechanism of action and broader role within peptide-mediated signalling networks.
